Immune-related adverse events and the balancing act of immunotherapy

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

Detalles Bibliográficos
Autores principales: Conroy, Michael, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770784/
https://www.ncbi.nlm.nih.gov/pubmed/35046403
http://dx.doi.org/10.1038/s41467-022-27960-2
_version_ 1784635443361349632
author Conroy, Michael
Naidoo, Jarushka
author_facet Conroy, Michael
Naidoo, Jarushka
author_sort Conroy, Michael
collection PubMed
description The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
format Online
Article
Text
id pubmed-8770784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87707842022-02-04 Immune-related adverse events and the balancing act of immunotherapy Conroy, Michael Naidoo, Jarushka Nat Commun Comment The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity. Nature Publishing Group UK 2022-01-19 /pmc/articles/PMC8770784/ /pubmed/35046403 http://dx.doi.org/10.1038/s41467-022-27960-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Conroy, Michael
Naidoo, Jarushka
Immune-related adverse events and the balancing act of immunotherapy
title Immune-related adverse events and the balancing act of immunotherapy
title_full Immune-related adverse events and the balancing act of immunotherapy
title_fullStr Immune-related adverse events and the balancing act of immunotherapy
title_full_unstemmed Immune-related adverse events and the balancing act of immunotherapy
title_short Immune-related adverse events and the balancing act of immunotherapy
title_sort immune-related adverse events and the balancing act of immunotherapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770784/
https://www.ncbi.nlm.nih.gov/pubmed/35046403
http://dx.doi.org/10.1038/s41467-022-27960-2
work_keys_str_mv AT conroymichael immunerelatedadverseeventsandthebalancingactofimmunotherapy
AT naidoojarushka immunerelatedadverseeventsandthebalancingactofimmunotherapy

Ejemplares similares